Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
06/2005
06/28/2005US6911524 Antimicrobial peptides derived from mollusks
06/28/2005US6911471 S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
06/28/2005US6911467 Useful for the treatment of type 2 diabetes, impaired glucose tolerance and certain other conditions
06/28/2005US6911454 By reversing or inhibiting the glycoprotein "pumps" associated with drug resistant cells
06/28/2005US6911439 Alpha 4 beta 1 integrin and CD49d/ CD29 (vla-4); antiinflammatory agents
06/28/2005US6911431 Pharmaceutical angiostatic dipeptide compositions and methods of use thereof
06/28/2005US6911430 Compositions and methods for treating ileus
06/28/2005US6911429 For therapy of arthritis, inflammatory dermatosis, inflammatory bowel disease, cancer, kidney fibrosis, inflammatory lung disease, obesity, lupus, cardiovascular disease and diabetes mellitus
06/28/2005US6911428 Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus
06/28/2005US6911427 No-modified hemoglobins and uses therefore
06/28/2005US6911426 Inhibitor of apoptosis proteins (IAP); survivin
06/28/2005US6911425 Integrin binding motif containing peptides and methods of treating skeletal diseases
06/28/2005US6911334 Protease for activating clotting factor VII
06/28/2005US6911323 Human coagulation factor VII polypeptides
06/28/2005US6911320 Pituitary tumor transforming gene (PTTG), formerly pituitary tumor specific gene (PTTG)
06/28/2005US6911316 Single chain urokinase type plasminogen activator (scuPA)/ soluble urokinase plasminogen activator receptor (suPAR); for the treatment/prevention of thromboembolic disorders associated with the formation of fibrin clots
06/28/2005US6911314 Screening for drugs that affect TNF receptor releasing enzyme
06/28/2005US6911227 Gels for encapsulation of biological materials
06/28/2005US6911220 Inactivating mature recipient t cells and introducing into a primate recipient fetal or neonatal thymic tissue from a donor of a different species; restoring thymus dependent ability for progenitors to develop into mature t cells
06/28/2005US6911218 Microparticles of a free carboxyl group polymer and a free amino group drug, dissolving in acetone, acetonitrile, ethyl acetate, tetrahydrofuran, or glyme and atomizing in a nozzle to an ethanol or isopropanol dispersion
06/28/2005US6911213 Pernasally absorbable insulin preparations
06/28/2005US6911212 New bone growth inducing compound of partially demineralized lyophilized allograft bone material having a residual calcium content of 4 to 8% dry weight.
06/28/2005US6911208 Fungicides; diagnosis of pityrosporum infection; antiallergens
06/28/2005US6911207 Cytotoxic T-cell epitopes of the papillomavirus L1-protein and use thereof in diagnostics and therapy
06/28/2005US6911206 Fusion proteins comprising carriers that can induce a dual immune response
06/28/2005US6911204 Administering chimera protein
06/28/2005US6911200 Administering a target cell-specific adenovirus vector, comprising an adenoviral gene essential for replication under transcriptional control of a target cell-specific transcriptional regulatory element and an anticancer agent
06/28/2005US6911198 Administering interferons in situ
06/28/2005US6911178 Contacting the sample containing an antibody specific for isolated and purified antigenically-active blood group antigen protein or peptide to allow the formation of an immune complex; and detecting the immune complex
06/28/2005CA2317411C Controlled release delivery of peptide or protein
06/28/2005CA2271196C Pharmaceutical compositions of hiv protease inhibitors with improved oral bioavailability
06/28/2005CA2252661C Storage stable dentifrice composition containing casein glycomacropeptide
06/28/2005CA2232230C Phosphopantetheinyl transferases and uses thereof
06/28/2005CA2133831C Low toxicity interleukin-2 analogues for use in immunotherapy
06/28/2005CA2129660C Tissue plasminogen activator glycosylation variants with improved therapeutic properties
06/28/2005CA2113663C Process for the obtention of a biological adhesive made of concentrated coagulation factors by acidic precipitation
06/26/2005CA2486245A1 Albumin having enhanced antimicrobial activity
06/23/2005WO2005057222A2 Use of t-cadherin as a target
06/23/2005WO2005057218A2 Methods of identifying modulators of apoptosis from parasites and uses thereof
06/23/2005WO2005056825A1 Screening for modulators of mekk2 and mekk3
06/23/2005WO2005056802A2 Materials and methods relating to cell cycle control
06/23/2005WO2005056801A1 Polynucleotides and polypeptides isolated from lactobacillus rhamnosus hn001 materials incorporating them and methods for using them
06/23/2005WO2005056795A2 Hif oligonucleotide decoy molecules
06/23/2005WO2005056791A1 Novel plexin polypeptide, dna encoding the same and use thereof
06/23/2005WO2005056784A1 Insulin-inducible polypeptide
06/23/2005WO2005056778A1 Method of regulating the differentiation of hematopoietic stem cells or proliferating the same
06/23/2005WO2005056762A2 Truncated cmv promoters and vectors containing same
06/23/2005WO2005056760A2 Glycopegylated follicle stimulating hormone
06/23/2005WO2005056756A2 Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis
06/23/2005WO2005056752A2 Methods and compositions for delivering polynucleotides
06/23/2005WO2005056598A2 Laminin-5 modulators and uses thereof
06/23/2005WO2005056594A1 Akt ACTIVITY SPECIFICALLY INHIBITING POLYPEPTIDE
06/23/2005WO2005056591A1 Glycine-rich proteins, their coding sequences and applications
06/23/2005WO2005056590A1 Novel interaction between proteins, therapeutic agent for disuse atrophy utilizing the novel interaction, and method relating to disuse atrophy
06/23/2005WO2005056581A2 Peptide able to specifically bind a chemokine receptor and use thereof
06/23/2005WO2005056580A1 Tetrapeptide regulating blood glucose level in diabetes mellitus
06/23/2005WO2005056579A1 Interleukin 6 crystals having novel crystalline structure
06/23/2005WO2005056578A2 High-level expression of fusion polypeptides in plant seeds utilizing seed-storage proteins as fusion carriers
06/23/2005WO2005056577A2 Peptide inhibitors of hiv
06/23/2005WO2005056572A2 Clustered multi-antigenic carbohydrate constructs, methods for their preparation and uses thereof
06/23/2005WO2005056551A2 Novel 2-hydroxytetrahydrofurane derivatives and use thereof as medicaments
06/23/2005WO2005056055A2 METHODS OF PROTECTING AGAINST RADIATION USING INDUCERS OF NF-κB
06/23/2005WO2005056054A2 METHODS OF INHIBITING APOPTOSIS USING INDUCERS OF NF-κB
06/23/2005WO2005056053A1 Use of goat serum for veterinary treatment
06/23/2005WO2005056050A1 Botulinum toxin therapy for skin disorders
06/23/2005WO2005056049A1 Methods and compounds for modulating triglyceride and vldl secretion
06/23/2005WO2005056048A1 Method for specifically increasing the sensitivity of tumor cells
06/23/2005WO2005056047A1 Use of sialic acid, analogues of sialic acid, and antibodies to sialidases as anti-infectious agents and anti-inflammatory agents
06/23/2005WO2005056046A2 Methods for treating inflammation using thyroid stimulating hormone
06/23/2005WO2005056045A1 Methods and compositions related to plunc polypeptides
06/23/2005WO2005056044A1 Use of c-reactive protein to treat immune complex-mediated renal disease
06/23/2005WO2005056043A2 Use of enzymatic inhibitors of h-prune for the prevention and treatment of the metastases of tumours overexpressing h-prune
06/23/2005WO2005056042A2 Methods of protecting against radiation using flagellin
06/23/2005WO2005056041A2 METHODS OF INHIBITING APOPTOSIS USING LATENT TGFβ
06/23/2005WO2005056040A2 Systems and methods related to degradation of uremic toxins
06/23/2005WO2005056039A1 Self-assembling peptide amphiphiles and related methods for growth factor delivery
06/23/2005WO2005056038A1 Pharmaceutical compositions and methods for insulin treatment
06/23/2005WO2005056037A1 Metered dose inhalation preparations of proteins and peptides
06/23/2005WO2005056036A2 Regulation of food preference using glp-1 agonists
06/23/2005WO2005056027A2 Solvent for biogenic active pharmaceutical ingredients
06/23/2005WO2005056024A1 Methods of enhancing stem cell engraftment
06/23/2005WO2005055994A1 Treatment and preventions of asthma
06/23/2005WO2005055983A2 Method of preparation of mixed phase co-crystals with active agents
06/23/2005WO2005055973A2 Endoparasiticidal agents for topical application
06/23/2005WO2005055945A2 Mucoadhesive drug delivery devices and methods of making and using thereof
06/23/2005WO2005055930A2 Recombinant factor viii having increased specific activity
06/23/2005WO2005042575A3 Method for down-regulation of vegf
06/23/2005WO2005042020A3 Combinations for hcv treatment
06/23/2005WO2005040210A3 Novel cxcl8 antagonists
06/23/2005WO2005039629A3 Caspase inhibitors as coating materiel for medical products for inhibiting restenosis
06/23/2005WO2005037999A9 Treatment of cancer using antibodies to lrrc15
06/23/2005WO2005037996A3 In vitro development of tissues and organs
06/23/2005WO2005035746A3 Medical use of tbk-1 or of inhibitors thereof
06/23/2005WO2005034978A3 MEDICAL USE OF IKKϵ OR OF INHIBITORS THEREOF
06/23/2005WO2005030119A3 Botulinum toxin a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
06/23/2005WO2005025593A3 Treatment of inflammatory respiratory diseases
06/23/2005WO2005023860A3 Modified il-4 mutein receptor antagonists
06/23/2005WO2005023232A3 Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders.
06/23/2005WO2005015205A3 Use of sap
06/23/2005WO2005009358A3 Conformationally constrained parathyroid hormone (pth) analogs
1 ... 1422 1423 1424 1425 1426 1427 1428 1429 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 ... 3163